Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

AZD2389

Small molecule · Inhibitor of fibroblast activation protein (FAP) · developed by ASTRAZENECA

Phase 2 Most advanced trial
AZN Developer

What is AZD2389?

AZD2389 is an oral small molecule that selectively inhibits fibroblast activation protein (FAP). It is being studied in chronic liver diseases with advanced hepatic fibrosis, including cirrhosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Active IMP
Drug type
Small molecule
Targets
fibroblast activation protein (FAP)
Mechanism
Inhibitor of fibroblast activation protein (FAP)
Therapy area
Gastroenterology
Developer
ASTRAZENECA (AZN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Hepatic CirrhosisLiver Fibrosis

Other drugs acting on FAP

More from ASTRAZENECA

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind AZD2389

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.